MX2018011109A - Composicion farmaceutica para el tratamiento y/o prevencion de cancer. - Google Patents

Composicion farmaceutica para el tratamiento y/o prevencion de cancer.

Info

Publication number
MX2018011109A
MX2018011109A MX2018011109A MX2018011109A MX2018011109A MX 2018011109 A MX2018011109 A MX 2018011109A MX 2018011109 A MX2018011109 A MX 2018011109A MX 2018011109 A MX2018011109 A MX 2018011109A MX 2018011109 A MX2018011109 A MX 2018011109A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
treating
preventing cancer
amino acid
fragment
Prior art date
Application number
MX2018011109A
Other languages
English (en)
Inventor
Okano Fumiyoshi
Fujita Takayuki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2018011109A publication Critical patent/MX2018011109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

La presente invención se refiere a una composición farmacéutica y similar para tratar y/o prevenir el cáncer, la composición farmacéutica contiene lo siguiente como ingredientes activos: una proteína MRAP2 que comprende una secuencia de aminoácidos representada por la SEQ ID NO: 2, 4, 6 u 8 o una secuencia de aminoácidos que tiene al menos 80% de identidad de secuencia con estas secuencias de aminoácidos o un fragmento de la proteína MRAP2 que contiene 7 o más aminoácidos continuos; y un anticuerpo que tiene reactividad inmunológica o un fragmento del mismo.
MX2018011109A 2016-03-28 2017-03-27 Composicion farmaceutica para el tratamiento y/o prevencion de cancer. MX2018011109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064033 2016-03-28
PCT/JP2017/012263 WO2017170334A1 (ja) 2016-03-28 2017-03-27 癌の治療及び／又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
MX2018011109A true MX2018011109A (es) 2018-11-09

Family

ID=59965476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011109A MX2018011109A (es) 2016-03-28 2017-03-27 Composicion farmaceutica para el tratamiento y/o prevencion de cancer.

Country Status (11)

Country Link
US (1) US20190112370A1 (es)
EP (1) EP3437656A4 (es)
JP (1) JP6939555B2 (es)
KR (1) KR102457956B1 (es)
CN (1) CN108883176A (es)
AU (1) AU2017244515B2 (es)
BR (1) BR112018069318A2 (es)
CA (1) CA3018154A1 (es)
MX (1) MX2018011109A (es)
RU (1) RU2746123C2 (es)
WO (1) WO2017170334A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
CA2508763C (en) 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
US20080299042A1 (en) * 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US9494210B2 (en) * 2006-08-04 2016-11-15 Honda Motor Co., Ltd. Vehicle mount and method
WO2012142330A1 (en) * 2011-04-15 2012-10-18 Brown University Micro rnas as diagnostic biomarkers and therapeutics for ovarian cancer and metastatic tumors that disseminate within the peritoneal cavity
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
CN104395756A (zh) * 2012-06-18 2015-03-04 北卡罗莱纳大学查佩尔山分校 头颈癌预断方法
CA2917961A1 (en) * 2013-07-10 2015-01-15 Joseph A. Majzoub Mrap2 knockouts
JP6715491B2 (ja) * 2014-06-11 2020-07-01 Ｉｄａｃセラノスティクス株式会社 免疫チェックポイント制御剤の副作用低減方法
JP2016064033A (ja) 2014-09-25 2016-04-28 テルモ株式会社 機器の脱着構造およびこの機器の脱着構造を有する搬送カート

Also Published As

Publication number Publication date
KR102457956B1 (ko) 2022-10-24
JP6939555B2 (ja) 2021-09-22
US20190112370A1 (en) 2019-04-18
EP3437656A4 (en) 2019-11-13
WO2017170334A1 (ja) 2017-10-05
BR112018069318A2 (pt) 2019-01-22
JPWO2017170334A1 (ja) 2019-02-07
CA3018154A1 (en) 2017-10-05
AU2017244515A1 (en) 2018-10-11
CN108883176A (zh) 2018-11-23
AU2017244515B2 (en) 2024-03-07
RU2018137819A (ru) 2020-04-29
RU2746123C2 (ru) 2021-04-07
RU2018137819A3 (es) 2020-07-08
KR20180128936A (ko) 2018-12-04
EP3437656A1 (en) 2019-02-06

Similar Documents

Publication Publication Date Title
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
WO2015107363A3 (en) Mycobacterial antigen composition
PH12017502323A1 (en) Novel xylanase
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
CO2019012204A2 (es) Proteínas de unión al antígeno anti-jagged1
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
MX2018011109A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
ZA202110285B (en) Antibodies and methods of use
MX2018011133A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2019007375A (es) Variante de enzima lipolitica.